In yesterday’s Wall Street session, Standard BioTools Inc (NASDAQ:LAB) shares traded at $1.55, down -4.91% from the previous session.
LAB stock price is now -23.18% away from the 50-day moving average and -32.63% away from the 200-day moving average. The market capitalization of the company currently stands at $575.28M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $3.50, TD Cowen recently initiated with Buy rating for Standard BioTools Inc (NASDAQ: LAB). On April 04, 2024, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $3.25, while ‘KeyBanc Capital Markets’ rates the stock as ‘Overweight’
In other news, Casdin Partners Master Fund, L, Director bought 550,000 shares of the company’s stock on Aug 13 ’24. The stock was bought for $890,560 at an average price of $1.62. Upon completion of the transaction, the Director now directly owns 50,575,821 shares in the company, valued at $78.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 09 ’24, Director Casdin Partners Master Fund, L bought 525,408 shares of the business’s stock. A total of $848,481 was incurred on buying the stock at an average price of $1.61. This leaves the insider owning 49,525,821 shares of the company worth $76.77 million. A total of 2.65% of the company’s stock is owned by insiders.
During the past 12 months, Standard BioTools Inc has had a low of $1.21 and a high of $3.16. As of last week, the company has a debt-to-equity ratio of 0.18, a current ratio of 3.88, and a quick ratio of 3.53. The fifty day moving average price for LAB is $1.9992 and a two-hundred day moving average price translates $2.29865 for the stock.
The latest earnings results from Standard BioTools Inc (NASDAQ: LAB) was released for 2021-12-31. The net profit margin was -120.81% and return on equity was -59.79% for LAB. The company reported revenue of $37.2 million for the quarter, compared to $27.67 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 34.48 percent.
